Perfluorohexyl Octane Eye Drops (Miebo) is a semifluorinated alkane ophthalmic solution. It was first approved in the United States in 2023 and is specifically used to treat the signs and symptoms of dry eye disease. Its unique mechanism enables it to form a monomolecular layer at the air-liquid interface of the tear film, thereby reducing evaporation.

How to Use Perfluorohexyl Octane Eye Drops (Miebo)

Routine Administration Regimen

The recommended usage of Perfluorohexyl Octane Eye Drops is 4 times a day, 1 drop into the affected eye each time.

Contact lenses must be removed before instilling the eye drops, and you should wait for at least 30 minutes after medication before reinserting them.

Wash your hands thoroughly before use, and avoid contact between the bottle tip and the eye or any surfaces to prevent contamination.

Specific Operating Steps

Step 1: Unscrew the cap of the eye drop bottle.

Step 2: Keep the bottle upright and gently squeeze the bottle body.

Step 3: While squeezing, invert the bottle and release the pressure (to allow air to be sucked back into the bottle).

Step 4: Keep the bottle inverted, place the bottle tip above the eye, and squeeze the bottle again to let the liquid drop into the eye. If both eyes need treatment, repeat the above steps for the other eye.

Dosage Adjustment of Perfluorohexyl Octane Eye Drops (Miebo)

Fixed Dosage with No Need for Adjustment

Based on clinical trial data, Perfluorohexyl Octane Eye Drops adopt a fixed dosage regimen, and no dosage adjustment is required for adult or elderly patients.

Handling of Special Situations

Allergic Reactions: If a patient experiences a hypersensitivity reaction to perfluorohexyl octane or any of its ingredients, the medication should be discontinued immediately.

Blurred Vision: Approximately 1-4% of patients may experience temporary blurred vision after using the medication. It is recommended to close the eyes for a moment after instillation and wait until vision is restored before driving or performing precision operations.

Medication for Special Populations with Perfluorohexyl Octane Eye Drops (Miebo)

Pregnant and Lactating Women

Pregnant Women: Currently, there are insufficient controlled studies on pregnant women.

Lactating Women: It is not yet clear whether perfluorohexyl octane is excreted in human milk. During medication, the benefits of breastfeeding and the mother’s treatment needs must be comprehensively considered.

Children and Elderly People

Children: The efficacy of the medication in patients under 18 years of age has not been established, so its use is not recommended.

Elderly People: Clinical studies have shown that there is no significant difference in efficacy between elderly patients and younger patients, and no special dosage adjustment is required.

Contact Lens Wearers

Perfluorohexyl Octane Eye Drops must not be used while wearing contact lenses.

Contact lenses need to be removed before medication, and you can only reinsert them at least 30 minutes after instilling the eye drops. This is to avoid interactions between the medication and the lenses or impacts on the therapeutic effect.